罗格列酮

罗格列酮对老年胰岛素抵抗患者血清C反应蛋白水平的影响

Effect of rosiglitazone on serum C-reaction protein in the elderly with insulin resistance

C组，大剂量罗格列酮组；

C , high dose rosiglitazone group ;

肥胖大鼠血清C反应蛋白水平的动态变化及罗格列酮干预的影响

Dynamic changes of serum C-reaction protein levels in diet-induced obese rats and effect of rosiglitazone intervention

E组，小剂量罗格列酮组。

E , low dose rosiglitazone group .

结论（1）罗格列酮可明显改善MS患者的胰岛素抵抗；

Conclusion ( 1 ) ROS can improve insulin sensitivity of the patients with MS.

HPLC法测定复方罗格列酮盐酸二甲双胍片中罗格列酮的含量α－酮戊二酸途径α

Determination of Rosiglitazone in Compound Rosiglitazone Metformin Tablet by HPLC - ketoglutarate pathway

结果提示，罗格列酮能降低X综合症大鼠的血压，减轻胰岛素抵抗，纠正糖、脂代谢紊乱。

Conclusions Rosiglitazone can reduce BP , improve insulin resistance and correct the abnormity of sugar and lipid metabolism .

非诺贝特及罗格列酮对高糖培养肾小球系膜细胞核因子κB信号通路调控的影响

Effects of fenofibrate and rosiglitazone on signal passway of nuclear factor - κ B in glomerular mesangial cells incubated with high concentration of glucose

罗格列酮干预对老年SD大鼠氧自由基及相关生化指标的影响

Effect of Rosiglitazone on oxygen free radical and biochemical parameters in aged SD rats

罗格列酮对鼠血管平滑肌细胞血管紧张素Ⅱ1型受体mRNA表达的影响

Effect of rosiglitazone on the expression of angiotensin ⅱ type 1 receptor mRNA in mice vascular smooth muscle cells

SD大鼠随机分为：对照组I、R组、IR+替米沙坦组、IR+罗格列酮组。

SD rats were randomly divided into control , IR , IR + telmisartan and IR + rosiglitazone group .

罗格列酮提高胰岛素抵抗大鼠大网膜脂肪细胞PPAR-γmRNA的表达水平

Experimental study of Rosiglitazone tablets effect on PPAR - γ mRNA 's expression of greater omental adipocyte in IR rats

慢性胰腺炎大鼠肝细胞IR、IRS-1mRNA的表达及罗格列酮的干预作用

The Expression of IR 、 IRS-1 mRNA of Hepatic Cell of Chronic Pancreatitis Rats and the Intervention of Rosiglitazone

罗格列酮对高糖刺激的大鼠肾小球系膜细胞B1整合素、ICAM-1表达的影响

Effects of Rosiglitazone on the Expression of β _1 Integrin and ICAM-1 in High Glucose-induced Rat Glomerular Mesangial Cells

结论罗格列酮对DES诱发的大鼠PRL腺瘤有治疗作用。

Conclusion Rosiglitazone has therapeutic effect against DES-induced prolactinoma in rats .

罗格列酮抑制HL-60细胞增殖和诱导分化作用

Effects of rosiglitazone on proliferation and differentiation of HL - 60 cell

罗格列酮对肝星状细胞MMP-2、TIMP-1mRNA表达的影响

Effects of Rosiglitazone on expressions of MMP-2 and TIMP-1 mRNA in hepatic stellate cells

罗格列酮对日本血吸虫病肝纤维化小鼠肝组织核因子-κB和过氧化物酶体增殖物激活受体γ表达的影响

Effect of rosiglitazone on the activity of hepatic nuclear factor-kappa B and expression of peroxisome proliferator-activated receptor - γ in mice with liver fibrosis due to schistosoma japonicum infection

不同浓度的盐酸罗格列酮干预后，与AGEs组对比A值均明显下降（P<0.05）；

Compared with AGEs group , A value was significantly reduced in the different dose RGZ groups ( P < 0.05 ) .

溃疡性结肠炎中PPARγ的表达和罗格列酮的治疗作用

The PPAR γ on Ulcerative Colitis and Therapeutic Effect of Rosiglitazone

伊贝沙坦与合用罗格列酮对胰岛素抵抗SD大鼠脂蛋白酯酶影响的对比研究

Contrast study of the effect of Irbesartan and Irbesartan combined Rosiglitazone on lipoprotein lipase of insulin resistance SD rats

罗格列酮对不同浓度葡萄糖条件下小鼠胰岛B细胞株NIT-1增殖、凋亡及功能的影响

Influence of Rosiglitazone on B Cells Line NIT-1 Proliferation , Apoptosis and Secretion in High Glucose

罗格列酮钠对非酒精性脂肪肝大鼠COX-2表达的影响

Effect of Rosiglitazone on the expression of COX-2 protein in non alcoholic fatty liver disease rats

罗格列酮改善PCOS患者的生殖和内分泌功能

Rosiglitazone improves the endocrine-reproductive function of PCOS patients

目的了解那格列奈和罗格列酮分别治疗2型糖尿病对血清超敏C反应蛋白（hsCRP）的影响。

Objective To investigate the effects of nateglinide and rosiglitazone on hypersensitivity C-reactive protein ( hs-CRP ) in type 2 diabetes .

用罗格列酮处理后能显著降低ET-1和MDA，提高NO、SOD和NOS活性水平。

Rosiglitazone treatment remarkably reduced ET-1 and MDA , while NO , SOD and NOS activity levels were significantly increased .

在蛋白水平探讨罗格列酮对炎症反应标志性蛋白的影响，用westernblot的方法检测LPS和罗格列酮作用前后iNOS的表达变化。

To study the influence of rosiglitazone on the inflammatory marker protein , iNOS expression was measured with Western blot . 3 .

PPARγ激活剂罗格列酮对兔动脉粥样硬化斑块消退的影响

Effect of PPAR γ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits

结论IR患者存在低度炎症状态，罗格列酮在改善IR及其相关代谢指标的同时，可降低CRP。

Conclusion Patients with IR have low degree inflammation state , rosiglitazone can improve insulin resistance and related metabolic disturbance with CRP reduction .

脂肪肝+罗格列酮组和糖尿病组FFA减低（P<0.05）。

Rosiglitazone and diabetes caused an reduction of FFA ( P < 0.05 ) .